Cargando…

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis

Osteoporosis is a significant concern for postmenopausal women and is a critical factor in hip fracture. Examining evidence for osteoporosis medications in hip fracture is important for optimizing treatment. PURPOSE: Review risedronate’s role for hip fracture in postmenopausal women. METHODS: A lite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gates, Brian J., Das, Shyamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Expert Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260522/ https://www.ncbi.nlm.nih.gov/pubmed/22267947 http://dx.doi.org/10.4137/CMAMD.S4092

Ejemplares similares

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
por: Kinov, Plamen, et al.
Publicado: (2012)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Use of risedronate for consolidation and callus formation in Colles fractures in postmenopausal women: SOLID study
por: Oliveira, Lindomar Guimarães, et al.
Publicado: (2015)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women
por: Osaki, M., et al.
Publicado: (2011)

Analysis of Related Factors of Brittle Hip Fracture in Postmenopausal Women with Osteoporosis
por: Zhuang, Hua‐feng, et al.
Publicado: (2020)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
por: McClung, Michael R., et al.
Publicado: (2012)

Progress in osteoporosis and fracture prevention: focus on postmenopausal women
por: Saag, Kenneth G, et al.
Publicado: (2009)

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
por: McClung, M. R., et al.
Publicado: (2012)

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women
por: El Maghraoui, Abdellah, et al.
Publicado: (2014)

Determinants of imminent fracture risk in postmenopausal women with osteoporosis
por: Barron, R. L., et al.
Publicado: (2020)

Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis
por: Roux, C, et al.
Publicado: (2008)

Costs of incident non-hip osteoporosis-related fractures in postmenopausal women from a payer perspective
por: Barcelos, Anabela, et al.
Publicado: (2023)

Anabolic treatments for osteoporosis in postmenopausal women
por: Hassan, Neelam, et al.
Publicado: (2021)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2017)

Osteoporosis and fracture risk assessment: improving outcomes in postmenopausal women
por: Perez, Mariana Ortega, et al.
Publicado: (2023)

Role of Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures: A Literature Review
por: Imam, Bashir, et al.
Publicado: (2019)

Resurfacing total hip replacement–a therapeutical approach in postmenopausal women with osteoporosis and hip arthrosis
por: Popescu, D, et al.
Publicado: (2011)

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023)

Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
por: Vestergaard, Peter, et al.
Publicado: (2010)

Higher serum uric acid levels are associated with reduced risk of hip osteoporosis in postmenopausal women with rheumatoid arthritis
por: Lee, Han-Na, et al.
Publicado: (2020)

Primary osteoporosis in postmenopausal women
por: Ji, Meng-Xia, et al.
Publicado: (2015)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Effect of medications and epidural steroid injections on fractures in postmenopausal women with osteoporosis
por: Kim, Minsoo, et al.
Publicado: (2019)

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2018)

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
por: Silverman, S. L., et al.
Publicado: (2006)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies
por: Korkes, Fernando, et al.
Publicado: (2021)

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_23megnsl5poetq62iodcm3c24b